Please check your internet connection and try again.
# Diloxanide furoate
## Overview
Diloxanide furoate is an amoebicide effective against the luminal (intestinal) forms of *Entamoeba histolytica*. It is not effective against invasive amoebiasis.
## Primary Indications
* Treatment of asymptomatic cyst passers of *Entamoeba histolytica*.
* Treatment of intestinal amoebiasis (amoebic dysentery), usually in conjunction with another agent for invasive disease.
## Adult Dosing
* 500 mg orally three times daily for 10 days.
## Pediatric Dosing
* **1 to 11 years:** 3.5 mg/kg orally three times daily for 10 days.
* **12 years and older:** 500 mg orally three times daily for 10 days.
* **Maximum pediatric dose:** Not established for children under 12; however, the adult dose is generally considered the maximum.
## Dose Adjustments
No specific dose adjustments are typically required for renal or hepatic impairment due to limited systemic absorption.
## Contraindications
* Known hypersensitivity to diloxanide furoate or any component of the formulation.
## Adverse Effects
The most common adverse effects are gastrointestinal, including nausea, vomiting, abdominal cramps, and diarrhea. Other reported adverse effects include headache, dizziness, and pruritus.
## Key Drug Interactions
No clinically significant drug interactions have been well-established.
## Monitoring
* Monitor for resolution of symptoms and confirmation of parasite eradication if indicated by local guidelines or clinical suspicion.
## Clinical Pearls
* Diloxanide furoate is poorly absorbed systemically, making it primarily effective for luminal amoebiasis.
* It is often used as a follow-up treatment to eradicate residual luminal cysts after treatment for invasive amoebiasis with metronidazole or a similar agent.
* Ensure adequate hydration, especially if diarrhea is present.
***
***Disclaimer:** This information is intended for clinical pharmacy use and does not substitute for professional medical judgment. Always verify current prescribing information with official drug compendia and institutional protocols before making clinical decisions.*
